Frontlight ResearchEarly access
Active, not recruitingNo phase
Biomarkers in the Brain Oxygen Optimization in Severe Traumatic Brain Injury Trial
Key facts
- Who runs it
- University of Pennsylvania
- Where
- Ann Arbor and Philadelphia, United StatesSee the 2 sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 300 people, planned
- Started
- 20 Dec 2020
- Expected to end
- 31 Dec 2027
- Type of study
- Observational
- Treatments tested
- No intervention. This is an observational study.
- Record updated
- 6 May 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Enrolled in BOOST-3 (this is an ancillary study to the BOOST-3 trial)
- BOOST-3 participant is enrolled at a BioBOOST site
- Able to maintain initial blood sample within 24 hours of injury
- Provide proxy informed consent
Who cannot take part
- Age less than 18 years
- Profoundly anemic (subjects who are profoundly anemic require blood transfusion)
Where in United States
- University of MichiganAnn Arbor, United States
- Penn Presbyterian Medical CenterPhiladelphia, United States
About the trial
What the trial wants to find out
BioBOOST is a multicenter, observational study of the effect of derangements in brain physiologic parameters on brain injury biomarker levels in patients with severe traumatic brain injury.
The group in the trial
- Severe traumatic brain injury (TBI)
This observational study is ancillary to the Brain Oxygen Optimization in Severe TBI Phase 3 (BOOST-3) trial (NCT 03754114). All participants in Bio-BOOST are enrolled in BOOST-3.
Treatment: No intervention. This is an observational study.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Biomarkers in the Brain Oxygen Optimization in Severe Traumatic Brain Injury Trial (BioBOOST)
- Record updated
- 6 May 2026